Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437998 | 1.00 | JAK2 (0.41) | JAK2MEN1KMT2ASUV39H2HPGD | |
| SCHEMBL9923783 | 0.88 | EPHX2 (0.41) | JAK2MEN1KMT2ASUV39H2HPGD | |
| SCHEMBL29438005 | 0.88 | EPHX2 (0.41) | JAK2MEN1KMT2ASUV39H2HPGD | |
| SCHEMBL17180631 | 0.84 | XIAP (0.46) | JAK2MEN1KMT2AKDM4E | |
| SCHEMBL29438013 | 0.83 | XIAP (0.50) | MAPTTHRB | |
| SCHEMBL9923798 | 0.83 | XIAP (0.50) | MAPTTHRB | |
| SCHEMBL15303385 | 0.80 | RAF1 (0.35) | KMT2AMAPTRAF1 | |
| SCHEMBL12594158 | 0.75 | MTNR1B (0.46) | JAK2MEN1KMT2ASUV39H2HPGD | |
| SCHEMBL12593803 | 0.73 | MTNR1B (0.46) | JAK2MEN1KMT2ASUV39H2HPGD | |
| SCHEMBL29437992 | 0.72 | KIT (0.39) | MEN1KMT2ARAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-10265316-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUCTICS LIMITED (GB) | 2019-04-23 | — | — | US | disclosed |
| US-20170273981-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2017-09-28 | — | — | US | disclosed |
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-09-01 | — | — | US | disclosed |
| US-9346790-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| EP-2649066-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | JAK2 3204/4885MEN1 1596/4885KMT2A 635/4885 |
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | JAK2 3237/4885MEN1 1367/4885KMT2A 450/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | JAK2 3204/4885MEN1 1596/4885KMT2A 635/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | JAK2 3204/4885MEN1 1596/4885KMT2A 635/4885 |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | JAK2 3204/4885MEN1 1596/4885KMT2A 635/4885 |
| US-20170273981-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | JAK2 3237/4885MEN1 1367/4885KMT2A 450/4885 |
| US-10265316-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNA3, KCND3, KCNN3 | JAK2 3237/4885MEN1 1367/4885KMT2A 450/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | JAK2 3237/4885MEN1 1367/4885KMT2A 450/4885 |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | JAK2 3204/4885MEN1 1596/4885KMT2A 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.